A non-mitogenic competitive hgf antagonist
CA 2091700 C · Owner: The United States Of America As Represented By The Secretary Department Of Health And Human Services · Inventors: Chan, Andrew M.-L.; Aaronson, Stuart A.; Rubin, Jeffrey S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a novel truncated form of hepatocyte growth factor (HGF) which specifically antagonizes the activity of HGF. In particular, the present invention relates to the purification, molecular cloning and recombinant expression of the truncated HGF variant. The present invention further relates to the utilization of the small HGF variants in the diagnosis and treatment of diseases in which cell proliferation is either excessive as in the case of malignancy or impaired due in part to aberrant expression of the various forms of HGF.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 10, 1991 and granted November 19, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 10, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 10, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.